Gene Expression Analysis Using a High-Resolution DNA Microarray of Peripheral Whole Blood Immediately Before and After Leukocytapheresis for Rheumatoid Arthritis

Therapeutic Apheresis and Dialysis

Volumn 16, Issue 5, 2012, Pages 456-466

  Kusaoi, Makio ^a   Yamaji, Ken ^a   Murayama, Go ^a   Yasui, Misa ^a   Yamada, Risa ^a   Hishinuma, Ruka ^a   Nemoto, Takuya ^a   Hohtatsu, Katsura ^a   Kageyama, Michiaki ^a   Kawamoto, Toshio ^a   Sugimoto, Kaoru ^a   Sekiya, Fumio ^a   Kon, Takayuki ^a   Ogasawara, Michihiro ^a   Kempe, Kazuo ^a   Tsuda, Hiroshi ^b   Takasaki, Yoshinari ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

Author keywords

Arthritis; Leukocytapheresis; Major histocompatibility complex; Oligonucleotide array sequence analysis; Rheumatoid; Signal transduction

Indexed keywords

DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; BLOOD; BLOOD SAMPLING; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HUMAN; LEUKAPHERESIS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKAPHERESIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84867375672     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01111.x     Document Type: Article

References (21)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Szekanecz Z, Besenyei T, Paragh G, Koch AE. Angiogenesis in rheumatoid arthritis. Autoimmunity 2009;42:563-73.
3. Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998;20:133-47.
4. Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol 2010;28:S52-57.
5. Gaujoux-Viala C, Smolen JS, Landewé R etal. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.
6. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF etal. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
7. Breedveld FC, Weisman MH, Kavanaugh AF etal. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
8. Emery P, Breedveld FC, Hall S etal. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
9. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32.
10. Yamaji K, Tsuda H, Hashimoto H. Current topics on cytapheresis technologies. Ther Apher 2001;5:287-92.
11. Yamaji K, Yang K, Tsuda H, Hashimoto H. Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther Apher 2002;6:402-12.
12. Kempe K, Tsuda H, Yang K, Yamaji K, Kanai Y, Hashimoto H. Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotrexate. Ther Apher Dial 2004;8:197-205.
13. Onuma S, Yamaji K, Kempe K etal. Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis. Ther Apher Dial 2006;10:404-11.
14. Yamaji K, Onuma S, Yasuda M, Kanai Y, Tsuda H, Takasaki Y. Fluctuations in peripheral blood leukocyte and platelet counts and leukocyte recruitment with large volume leukocytapheresis in healthy volunteers. Ther Apher Dial 2006;10:396-403.
15. Eguchi K, Saito K, LCAP Investigators in the Kyushu College of Rheumatology (LIKCR) etal. Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. Mod Rheumatol 2007;17:481-5.
16. Hidaka T, Suzuki K, Matsuki Y etal. Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. Ther Apher 1999;3:178-85.
17. Hidaka T, Suzuki K, Kawakami M etal. Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher 2001;16:74-81.
18. Umekita K, Hidaka T, Ueno S etal. Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocyte-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis. Mod Rheumatol 2009;19:265-72.
19. Itoh Y, Takeshita Y, Ozawa Y, Tohma S, Umemura S. A case report of leukocytapheresis for refractory leg ulcers complicated with rheumatoid arthritis. Ther Apher Dial 2006;10:419-24.
20. Müller-Hilke B, Mitchison NA. The role of HLA promoters in autoimmunity. Curr Pharm Des 2006;12:3743-52.
21. Lie BA, Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr Opin Immunol 2005;17:526-31.